Cargando…

Calprotectin: a novel biomarker for the diagnosis of pleural effusion

BACKGROUND: Novel non-invasive biomarkers for the precise diagnosis of malignancy in pleural effusion (PE) are needed. The aim of this study was to determine the diagnostic accuracy of calprotectin for predicting malignancy in patients with exudative PE. METHODS: Calprotectin concentration was measu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sánchez-Otero, N, Blanco-Prieto, S, Páez de la Cadena, M, Vázquez-Iglesias, L, Fernández-Villar, A, Botana-Rial, M I, Rodríguez-Berrocal, F J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3504943/ https://www.ncbi.nlm.nih.gov/pubmed/23093228 http://dx.doi.org/10.1038/bjc.2012.478

Ejemplares similares

Levels of PEDF in Pleural Effusions from Lung Adenocarcinoma and Benign Disease Patients
por: Sánchez-Otero, Nuria, et al.
Publicado: (2013)

Validation of Calprotectin As a Novel Biomarker For The Diagnosis of Pleural Effusion: a Multicentre Trial
por: Botana-Rial, Maribel, et al.
Publicado: (2020)

Evaluation of pleural effusion sCD26 and DPP-IV as diagnostic biomarkers in lung disease
por: Sánchez-Otero, Nuria, et al.
Publicado: (2014)

A rapid calprotectin test for the diagnosis of pleural effusion
por: Casado-Rey, Pedro, et al.
Publicado: (2021)

Serum Calprotectin, CD26 and EGF to Establish a Panel for the Diagnosis of Lung Cancer
por: Blanco-Prieto, Sonia, et al.
Publicado: (2015)

Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion
por: Tsuji, S, et al.
Publicado: (2010)

Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma
por: Lemos-González, Y, et al.
Publicado: (2007)

Serum sCD26 for colorectal cancer screening in family-risk individuals: comparison with faecal immunochemical test
por: Otero-Estévez, O, et al.
Publicado: (2015)

Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma
por: Ghanim, B, et al.
Publicado: (2014)

Highly Sensitive Marker Panel for Guidance in Lung Cancer Rapid Diagnostic Units
por: Blanco-Prieto, Sonia, et al.
Publicado: (2017)

Relevance of matrix metalloproteases in non-small cell lung cancer diagnosis
por: Blanco-Prieto, Sonia, et al.
Publicado: (2017)

EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib
por: Kimura, H, et al.
Publicado: (2006)

Management of malignant pleural effusion by an indwelling pleural catheter: A cost-efficiency analysis
por: Rial, Maribel Botana, et al.
Publicado: (2015)

A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma
por: Kao, Steven C, et al.
Publicado: (2016)

A Study Investigating Markers in PLeural Effusion (SIMPLE): a prospective and double-blind diagnostic study
por: Han, Yan-Qiu, et al.
Publicado: (2019)

Pleural fluid analysis of lung cancer vs benign inflammatory disease patients
por: Kremer, R, et al.
Publicado: (2010)

Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells
por: Hoda, M A, et al.
Publicado: (2012)

Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis
por: Kirschner, Michaela B, et al.
Publicado: (2015)

CD74: a new prognostic factor for patients with malignant pleural mesothelioma
por: Otterstrom, C, et al.
Publicado: (2014)

The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma
por: Pinato, D J, et al.
Publicado: (2013)

Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells
por: Johansson, D, et al.
Publicado: (2010)

Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients
por: Jennings, C J, et al.
Publicado: (2015)

Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer
por: Anderson, K S, et al.
Publicado: (2011)

The diagnostic value of pleural fluid homocysteine in malignant pleural effusion
por: Santotoribio, Jose D., et al.
Publicado: (2019)

Salivary analysis of oral cancer biomarkers
por: Shpitzer, T, et al.
Publicado: (2009)

Faecal calprotectin to detect inflammatory bowel disease: a systematic review and exploratory meta-analysis of test accuracy
por: Freeman, Karoline, et al.
Publicado: (2019)

Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer—what has gone wrong? A blueprint for the way forward in biomarker studies
por: Huber, F, et al.
Publicado: (2015)

Midkine as a prognostic biomarker in oral squamous cell carcinoma
por: Ota, K, et al.
Publicado: (2008)

Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma
por: Greystoke, A, et al.
Publicado: (2011)

Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer
por: Ankeny, J S, et al.
Publicado: (2016)

Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes
por: Shapira, I, et al.
Publicado: (2014)

Identification of serum biomarkers for colon cancer by proteomic analysis
por: Ward, D G, et al.
Publicado: (2006)

Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer
por: Öhlund, D, et al.
Publicado: (2009)

Tissue biomarkers of breast cancer and their association with conventional pathologic features
por: Chung, L, et al.
Publicado: (2013)

Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review
por: Lampejo, T, et al.
Publicado: (2010)

Disseminated tumour cells as a prognostic biomarker in colorectal cancer
por: Flatmark, K, et al.
Publicado: (2011)

Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer
por: Kuefer, R, et al.
Publicado: (2005)

MDM2 is an important prognostic and predictive factor for platin–pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53
por: Walter, R F H, et al.
Publicado: (2015)

Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model
por: Fox, R, et al.
Publicado: (2014)

Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma
por: Jones, C I, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_1lpti0hstsil803kjdgtehh8ro